Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.
Stebbing J, Krishnan V, de Bono S, Ottaviani S, Casalini G, Richardson PJ, Monteil V, Lauschke VM, Mirazimi A, Youhanna S, Tan YJ, Baldanti F, Sarasini A, Terres JAR, Nickoloff BJ, Higgs RE, Rocha G, Byers NL, Schlichting DE, Nirula A, Cardoso A, Corbellino M; Sacco Baricitinib Study Group. Stebbing J, et al. Among authors: de bono s. EMBO Mol Med. 2020 Aug 7;12(8):e12697. doi: 10.15252/emmm.202012697. Epub 2020 Jun 24. EMBO Mol Med. 2020. PMID: 32473600 Free PMC article.
Baricitinib in Patients with Refractory Rheumatoid Arthritis.
Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, Beattie SD, Koch AE, Cardillo TE, Rooney TP, Macias WL, de Bono S, Schlichting DE, Smolen JS. Genovese MC, et al. Among authors: de bono s. N Engl J Med. 2016 Mar 31;374(13):1243-52. doi: 10.1056/NEJMoa1507247. N Engl J Med. 2016. PMID: 27028914 Free article. Clinical Trial.
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study.
Dougados M, van der Heijde D, Chen YC, Greenwald M, Drescher E, Liu J, Beattie S, Witt S, de la Torre I, Gaich C, Rooney T, Schlichting D, de Bono S, Emery P. Dougados M, et al. Among authors: de la torre i, de bono s. Ann Rheum Dis. 2017 Jan;76(1):88-95. doi: 10.1136/annrheumdis-2016-210094. Epub 2016 Sep 29. Ann Rheum Dis. 2017. PMID: 27689735 Free PMC article. Clinical Trial.
Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment.
Fleischmann R, Schiff M, van der Heijde D, Ramos-Remus C, Spindler A, Stanislav M, Zerbini CA, Gurbuz S, Dickson C, de Bono S, Schlichting D, Beattie S, Kuo WL, Rooney T, Macias W, Takeuchi T. Fleischmann R, et al. Among authors: de bono s. Arthritis Rheumatol. 2017 Mar;69(3):506-517. doi: 10.1002/art.39953. Arthritis Rheumatol. 2017. PMID: 27723271 Free PMC article. Clinical Trial.
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.
Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen Morales L, Reyes Gonzaga J, Yakushin S, Ishii T, Emoto K, Beattie S, Arora V, Gaich C, Rooney T, Schlichting D, Macias WL, de Bono S, Tanaka Y. Taylor PC, et al. Among authors: de bono s. N Engl J Med. 2017 Feb 16;376(7):652-662. doi: 10.1056/NEJMoa1608345. N Engl J Med. 2017. PMID: 28199814 Free article. Clinical Trial.
Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies.
Taylor PC, Kremer JM, Emery P, Zuckerman SH, Ruotolo G, Zhong J, Chen L, Witt S, Saifan C, Kurzawa M, Otvos JD, Connelly MA, Macias WL, Schlichting DE, Rooney TP, de Bono S, McInnes IB. Taylor PC, et al. Among authors: de bono s. Ann Rheum Dis. 2018 Jul;77(7):988-995. doi: 10.1136/annrheumdis-2017-212461. Epub 2018 Feb 20. Ann Rheum Dis. 2018. PMID: 29463520 Free PMC article. Review.
Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs.
van der Heijde D, Dougados M, Chen YC, Greenwald M, Drescher E, Klar R, Xie L, de la Torre I, Rooney TP, Witt SL, Schlichting DE, de Bono S, Emery P. van der Heijde D, et al. Among authors: de la torre i, de bono s. RMD Open. 2018 May 8;4(1):e000662. doi: 10.1136/rmdopen-2018-000662. eCollection 2018. RMD Open. 2018. PMID: 29765703 Free PMC article.
Characterization and Changes of Lymphocyte Subsets in Baricitinib-Treated Patients With Rheumatoid Arthritis: An Integrated Analysis.
Tanaka Y, McInnes IB, Taylor PC, Byers NL, Chen L, de Bono S, Issa M, Macias WL, Rogai V, Rooney TP, Schlichting DE, Zuckerman SH, Emery P. Tanaka Y, et al. Among authors: de bono s. Arthritis Rheumatol. 2018 Dec;70(12):1923-1932. doi: 10.1002/art.40680. Epub 2018 Oct 22. Arthritis Rheumatol. 2018. PMID: 30058112 Free PMC article.
Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19.
Sims JT, Krishnan V, Chang CY, Engle SM, Casalini G, Rodgers GH, Bivi N, Nickoloff BJ, Konrad RJ, de Bono S, Higgs RE, Benschop RJ, Ottaviani S, Cardoso A, Nirula A, Corbellino M, Stebbing J. Sims JT, et al. Among authors: de bono s. J Allergy Clin Immunol. 2021 Jan;147(1):107-111. doi: 10.1016/j.jaci.2020.08.031. Epub 2020 Sep 10. J Allergy Clin Immunol. 2021. PMID: 32920092 Free PMC article.
Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways.
Dörner T, Tanaka Y, Petri MA, Smolen JS, Wallace DJ, Dow ER, Higgs RE, Rocha G, Crowe B, Benschop RJ, Byers NL, Silk ME, de Bono S, Fantini D, Hoffman RW. Dörner T, et al. Among authors: de bono s. Lupus Sci Med. 2020 Oct;7(1):e000424. doi: 10.1136/lupus-2020-000424. Lupus Sci Med. 2020. PMID: 33037080 Free PMC article. Clinical Trial.
50 results